Crescent Biopharma (CBIO) EBIAT (2016 - 2026)
Crescent Biopharma has reported EBIAT over the past 12 years, most recently at -$23.3 million for Q1 2026.
- Quarterly EBIAT fell 53.7% to -$23.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$93.0 million through Mar 2026, down 140.79% year-over-year, with the annual reading at -$153.9 million for FY2025, 761.6% down from the prior year.
- EBIAT was -$23.3 million for Q1 2026 at Crescent Biopharma, roughly flat from -$23.3 million in the prior quarter.
- Over five years, EBIAT peaked at -$2.6 million in Q3 2024 and troughed at -$24.6 million in Q3 2025.
- The 5-year median for EBIAT is -$10.5 million (2023), against an average of -$13.4 million.
- Year-over-year, EBIAT soared 71.41% in 2024 and then tumbled 835.01% in 2025.
- A 5-year view of EBIAT shows it stood at -$10.2 million in 2022, then rose by 11.38% to -$9.1 million in 2023, then soared by 71.02% to -$2.6 million in 2024, then plummeted by 785.59% to -$23.3 million in 2025, then increased by 0.07% to -$23.3 million in 2026.
- Per Business Quant, the three most recent readings for CBIO's EBIAT are -$23.3 million (Q1 2026), -$23.3 million (Q4 2025), and -$24.6 million (Q3 2025).